Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?

BCR-ABL fusion gene t(9;22)(q34;q11) occurs in only 3% of pediatric acute lymphoblastic leukemia (ALL) cases. Previously, less than 40% of Philadelphia-positive ALL patients were cured with intensive chemotherapy. The use of imatinib (340 mg/m(2)/day) added to an intensive chemotherapy regimen has i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ay, Yilmaz, Yilmaz, Deniz, Balkan, Can, Karapinar, Bulent, Karadas, Nihal, Kavakli, Kaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Published: June 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130983/
https://www.ncbi.nlm.nih.gov/pubmed/21738503
http://dx.doi.org/10.1159/000330102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130983/
https://www.ncbi.nlm.nih.gov/pubmed/21738503
http://dx.doi.org/10.1159/000330102

Ejemplares similares